Boncz Imre, Sebestyén Andor, Gulácsi László, Pál Miklós, Dózsa Csaba
Országos Egészségbiztosítási Pénztár, Budapest 1139, Hungary.
Magy Onkol. 2003;47(2):149-54. Epub 2003 Sep 16.
The organized breast cancer screening programme has started in Hungary at the end of 2001.
To assess the screening rate, the cost of screening and treatment and to calculate the expected epidemiological and economic gain and cost-effectiveness of mass-screening programme.
The data derive from the financial database of the National Health Insurance Fund of Hungary from 2001. To assess the screening rate the authors used the code "No. 42400 mammography screening" of outpatient care. The cost of treatment includes the cost of outpatient care, the acute and chronic inpatient care, the subsidies of the prices of medicines and the expenditure on disability to work (including sickness-pay). The expected benefits of the screening programme were modeled with changing mortality decrease for a 10 years interval.
The screening rates of women aged 45-65 for 2001 and 2002 were 7% and 21.7%, respectively. The cost of treatment of breast cancer was around 8.6 billion Hungarian forints (29,939,868 USD, 33,426,321 EUR) in 2001. In the age-group 45-65 with 10% mortality decline 509 lives (net present value, NPV: 365), with 20% mortality decline 1.074 (NPV: 772) lives and with 30% mortality decline 1.582 (NPV: 1.139) lives can be saved during a 10 years screening programme. The cost of one life saved varies between 5.7 million forints (19,876 USD, 22,190 EUR)/life saved and 17.8 million forints (62,047 USD, 69,273 EUR)/life saved according to the mortality decline. The cost of one life year saved varies between 271,000 forints (946 USD, 1057 EUR)/life year saved and 847,000 forints (2955 USD, 3299 EUR)/life years saved.
The implementation of organized breast cancer screening can lead to cost savings in Hungary. The cost-effectiveness of breast cancer screening seems to be acceptable for purchaser.
匈牙利于2001年底启动了有组织的乳腺癌筛查项目。
评估筛查率、筛查及治疗成本，并计算大规模筛查项目预期的流行病学和经济效益以及成本效益。
数据来源于匈牙利国家健康保险基金2001年的财务数据库。为评估筛查率，作者使用了门诊护理代码“42400号乳房X光检查筛查”。治疗成本包括门诊护理成本、急性和慢性住院护理成本、药品价格补贴以及工作残疾支出（包括病假工资）。筛查项目的预期效益通过对10年期间死亡率下降变化进行建模得出。
2001年和2002年45 - 65岁女性的筛查率分别为7%和21.7%。2001年乳腺癌治疗成本约为86亿匈牙利福林（29,939,868美元，33,426,321欧元）。在45 - 65岁年龄组中，死亡率下降10%时，在10年筛查项目期间可挽救509条生命（净现值，NPV：365）；死亡率下降20%时，可挽救1074条生命（NPV：772）；死亡率下降30%时，可挽救1582条生命（NPV：1139）。根据死亡率下降情况，挽救一条生命的成本在570万福林（19,8
